Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

• Status: Completed
• Trial end date: 2019-08-13
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study are to investigate the safety and effectiveness of EYLEA

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients who start EYLEA treatment for Diabetic Macular Edema (DME)

Exclusion Criteria:

• Patients who have already received EYLEA treatment